Breast Cancer Coverage from Every Angle

Nadia Harbeck, MD, PhD: Expert Perspective on De-escalating Breast Cancer Therapy With Paclitaxel, Pertuzumab, and Trastuzumab

Posted: Tuesday, June 15, 2021

Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses the clinical implications of treating patients who have early breast cancer with a de-escalated regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.